PIERIS PHARMACEUTICALS CORPORATE PRESENTATION November 2022 SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, whether PRS-220 will ...

Financial Data and Key Metrics Changes - Cash and cash equivalents decreased to $80.9 million for the quarter ended June 30, 2022, down from $117.8 million for the quarter ended December 31, 2021, due to funding operations in the first half of 2022 [21] - R&D expenses were $11.9 million for the quarter ended June 30, 2022, compared to $15.8 million for the same quarter in 2021, reflecting lower program costs [21] - Net loss was $10.3 million or a loss of $0.14 per share for the quarter ended June 30, 2022, compared to a net loss of $15.5 million or a $0.25 loss per share for the same quarter in 2021 [22] Business Line Data and Key Metrics Changes - The lead respiratory program, PRS-060 (AZD1402), is currently in a Phase IIa study with AstraZeneca, focusing on moderate to severe asthma [7][8] - The company is winding down the CINRA program, which was a 4-1BB bispecific for gastric cancer, to focus resources on other programs [14][18] - PRS-220, a proprietary inhaled Anticalin protein for idiopathic pulmonary fibrosis, is expected to enter a Phase I study later this year [12] Market Data and Key Metrics Changes - The company is facing challenges in recruiting for respiratory clinical trials due to the ongoing impact of COVID-19, which has affected enrollment rates [9][45] - The company has made strategic decisions to simplify trial protocols to enhance recruitment rates [10][60] Company Strategy and Development Direction - The company is prioritizing its lead respiratory program, PRS-060, while also making high-impact investments in proprietary assets like PRS-220 [6][12] - The company is focusing on a streamlined pipeline and resource allocation to navigate the tough economic climate for small-cap biotech firms [6][20] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the tough economic climate and the need for focused decision-making due to resource constraints [6] - The company believes it is sufficiently funded into the second quarter of 2024, despite the challenges faced [20] Other Important Information - Dr. Tim Demuth, Senior Vice President and Chief Medical Officer, will be leaving the company [18] - The company has retained co-development and U.S. co-commercialization options for two discovery-stage programs with AstraZeneca [12] Q&A Session Summary Question: What data is AstraZeneca using to determine the optimal dose for PRS-060? - Management indicated that safety data from the 1 and 3-milligram cohorts and preclinical modeling informed the decision to focus on the 3-milligram dose [26][29] Question: Will the sample size for the 3-milligram efficacy trial be increased? - Management confirmed that the sample size will remain at 80 patients in both the placebo and treatment groups, as they believe it is well powered for the study [30][33] Question: What are the next steps after the Phase IIa data for PRS-060? - Management indicated that a Phase IIb is more probable than moving directly to Phase III, depending on the data readout [35][36] Question: What clinical benefits were observed in the CINRA program? - Management noted that the ongoing Phase II study showed responses consistent with the Phase I study, indicating clinical benefit [38] Question: How has COVID-19 impacted enrollment in asthma trials? - Management explained that COVID-19 has significantly affected recruitment and disease control, impacting the timelines for the trial [44][45] Question: What is the status of PRS-220's regulatory filing? - Management clarified that a regulatory filing has been submitted in Australia, similar to the approach taken with PRS-060 [51] Question: Are there any collaborations likely to deliver near-term milestones? - Management mentioned that while there are modest milestones expected from various partnerships, they are not of the magnitude seen with AstraZeneca [53]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State or other juri ...

PIERIS PHARMACEUTICALS CORPORATE PRESENTATION May 2022 SUPERIOR MEDICINES THROUGH EFFICIENT BIOLOGY Forward-Looking Statements This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the timing for initiation ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State or other jur ...

Pieris Pharmaceuticals, Inc (NASDAQ:PIRS) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Stephen S. Yoder – Chief Executive Officer, President, Director Thomas Bures – Senior Vice President, Chief Financial Officer Tim Demuth – Chief Medical Officer Conference Call Participants Jessica Hanitta Hui – Evercore ISI Roger Jiale Song – Jefferies Matthew Phipps – William Blair & Company Operator Good day and welcome to your Pieris Pharmaceuticals, Inc. First Quarter Earnings Call. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada EIN 30-0784346 (State or other juri ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2021 Earnings Conference Call March 1, 2022 8:00 AM ET Company Participants Stephen Yoder - CEO, President & Director Thomas Bures - SVP & CFO Shane Olwill - SVP & Chief Development Officer Conference Call Participants Jonathan Miller - Evercore ISI Matthew Phipps - William Blair & Company Roger Song - Jefferies Operator Greetings, and welcome to the Pieris Pharmaceuticals Year-End Earnings Call. [Operator Instructions]. As a reminder, this conference is being r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37471 PIERIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 30-0784346 (State or other juri ...